-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Yinnuo Pharmaceutical-B (02591) opened more than 13% higher, the potential contract value of the core product esupaglutide α went overseas with a potential contract value of more than 1 billion US dollars

Zhitongcaijing·11/20/2026 01:33:01
Listen to the news

The Zhitong Finance App learned that Yinnuo Pharmaceutical-B (02591) opened more than 13% higher. As of press release, it had risen 13.05% to HK$3.595, with a turnover of HK$1,678,900.

According to the news, on November 19, Yinnuo Pharmaceutical announced that the company has signed an exclusive licensing agreement with Arcera Life Sciences Ltd. to promote the development and commercialization of the innovative product esupaglutide α independently developed by Yinnuo Pharmaceutical in emerging markets around the world. According to the agreement, ArCera will obtain exclusive rights in esupaglutide α in some countries in Africa, Latin America, the Middle East and Eastern Europe, while Yinnuo Pharmaceuticals will retain related rights in other regions of the world.

Yinnuo Pharmaceuticals will receive a $38 million down payment and recent milestone payments (including a non-refundable down payment of $15 million) and a total potential contract value of over $1 billion based on double-digit royalties. The company said that this cooperation marks an important breakthrough in the launch of the GLP-1 innovative drug independently developed by China and commercialized, and will further promote the implementation of Yinnuo Pharmaceutical's internationalization strategy.